In a fresh development that has come as a big boost BBI stock, Brickell Biotech Inc (NASDAQ:BBI) released positive results from the Phase 2b clinical trial of one of its products. The product in question is a gel made of sofpironium bromide, which is meant for the treatment of primary hyperhidrosis, a condition that leads to heightened sweating in an individual’s underarms.
Big Relief
The data from the Phase 2b clinical trial was also published in the Journal of the American Academy of Dermatology. This is a significant development for Brickell, and the rally in BBI stock was not a complete surprise.
The company revealed that patients who had been administered three strengths of sofpironium bromide experienced significant improvement in their conditions. Results became visible by the eighth day of the treatment, and the improvement continued for the rest of the period.
BBI stock soared by as much as 99% to $3.62 this morning on the back of the news.
>> Three Small-Cap Healthcare Stocks to Keep Your Portfolio Looking Healthy
Deepak Chadha, who is the Chief Research and Development Officer at the company, stated that the findings from the clinical trial have given Brickell Biotech the confidence to move forward with further development of sofpironium bromide.
The company also revealed the details about the safety aspect of the product. Side effects of the medicine were mild, and the most recurring complaints were that of blurred vision or dry mouth.
A Phase 3 registration trial has already been conducted in Japan by the company’s Japanese partner, Kaken Pharmaceutical Co. Ltd. However, the all-important Phase 3 trial of sofpironium bromide in the United States is the next big event for Brickell Biotech. Today’s developments are vital for the company, and it would go a long way in shaping the next stage of the product’s development.
Despite today’s jump, BBI stock is still down over 52% over the past year.
Featured image: DepositPhotos © Mazirama
